Interesting-Patents.com
Invention Title:

PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION

Publication number:

US20240150398

Publication date:
Section:

Chemistry; metallurgy

Class:

C07K7/06

Inventor:

Applicant:

Drawings (4 of 14)

Drawing 01 for PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION
Drawing 02 for PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION
Drawing 03 for PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION
Drawing 04 for PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION

Smart overview of the Invention

Novel peptides and their conjugates have been developed to mimic the angiotensin-converting enzyme 2 (ACE-2) receptor and the S1 subunit of the spike protein of SARS-CoV-2. These peptides aim to prevent the virus from binding to host cells, thereby offering a potential strategy for controlling Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections.

Background on SARS-CoV-2

SARS-CoV-2 is responsible for the COVID-19 pandemic and is characterized by its ability to infect host cells through its spike protein, which interacts with ACE-2. Understanding this interaction is crucial for developing effective antiviral therapies, as current treatments are limited and the need for preventive measures remains high.

Peptide Design and Functionality

The peptides provided in this invention include specific amino acid sequences designed to bind to the S1 spike protein of SARS-CoV-2. Notably, sequences such as SEQ ID NO: 3 and SEQ ID NO: 4 have been identified as effective mimics. These peptides can be used alone or in combination, forming complexes that enhance their ability to inhibit viral entry into host cells.

Conjugates and Pharmaceutical Applications

The invention also encompasses conjugates where these mimic peptides are attached to nanoparticles ranging from 10 nm to 20 nm in size. These conjugated peptides can be formulated into pharmaceutical compositions that include various carriers like saline or buffered solutions, enhancing their delivery and efficacy in treating or preventing SARS-CoV-2 infections.

Methods of Use

Methods for using these peptides include administering them in effective amounts to inhibit SARS-CoV-2 infection in subjects. By blocking the interaction between the virus's spike protein and the ACE-2 receptor on host cells, these peptides offer a promising approach for both therapeutic and prophylactic applications against COVID-19.